The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Abstract
The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration constraints of oral semaglutide, orforglipron offers a major convenience advantage: it is a small molecule with ~79% oral bioavailability that requires no food or water restrictions. Mechanistically, it acts by stimulating cyclic adenosine monophosphate without inducing β-arrestin recruitment, thus potentially limiting receptor desensitization and tachyphylaxis. Phase 3 trials demonstrated potent, dose-dependent efficacy. In the ACHIEVE-3 head-to-head trial (T2DM), orforglipron 36 mg proved superior to oral semaglutide 14 mg, delivering significantly greater reductions in hemoglobin A1c (–2.2% vs –1.4%) and body weight (–9.2% vs –5.3%). In the ATTAIN-2 trial (obesity and T2DM), the same dose achieved 10.5% mean weight loss. The safety profile is consistent with the GLP-1 RA class, dominated by manageable gastrointestinal events mitigated by slow dose escalation. A nondose-dependent heart rate increase and a small signal for mild pancreatitis were observed. A class-specific concern exists regarding increased ventricular arrhythmia risk in patients with heart failure with reduced ejection fraction treated with conventional GLP-1 RAs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mechanistic substudies suggest that orforglipron engages central appetite pathways similarly to peptide GLP-1 RAs, contributing to reductions in caloric intake and body weight independent of glucose lowering [44].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [44]
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Research works printed but not linked: 2
- Emmerich, 2024, Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023., NCHS Data Brief
- Anderer, 2025, FDA approves tirzepatide as first drug for obstructive sleep apnea., JAMA, 333, 656
Cited by
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
“Mechanistic substudies suggest that orforglipron engages central appetite pathways similarly to peptide GLP-1 RAs, contributing to reductions in caloric intake and body weight independent of glucose lowering [44].”
Morse, B. L., Coutant, D. E., Ma, X., Raha, S., Aithal, K., Nicoll, C., Rougée, L. R. A., & Bhattachar, S. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70377 · Cited by 4
Zaman, W., & Amin, A. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2676109 · Cited by 2
“Its mechanism of action is consistent with the established therapeutic biology of GLP-1 signaling [40].”
InfluentialPillai, A. A., Godin, S., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001310 · Cited by 1
Self-citationCastro-Gamboa, J. A., Mora-Jiménez, J., Arguedas‐Chacón, S., & Zavaleta‐Monestel, E. (2026) · Cureus · doi:10.7759/cureus.110178
“By contrast, the largest volume of literature consisted of reviews and evidence syntheses, which were essential for contextualization but did not fully resolve the question of superiority across the marketed GLP-1 receptor agonist class [2,12,13,15,20-36].”
Metadata
- Authors
- Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S.
- Affiliations
- Virginia Commonwealth University (US)
- Yale New Haven Hospital (US)
- Westchester Medical Center (US)
- Corresponding author
- Pillai, Ashwin A.
- Krayem, Hussein
- Venue
- Cardiology in Review
- Published
- 2025-12-16
- ISSN
- 1061-5377 (ISSN-L)
- 1538-4683
- OpenAlex
- W4417350225
- Semantic Scholar
- ae02303ff9822c14ead97fdb90ad21cbd3ca5266
- Cited by
- 3
- References
- 57
- Citations by year
- 2026: 3
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiology in Review (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- orforglipron, oral GLP-1 receptor agonists, obesity, type 2 diabetes, semaglutide, oral bioavailability, cAMP signaling, beta-arrestin, receptor desensitization, tachyphylaxis, glycemic control, weight loss, gastrointestinal adverse effects, heart rate increase, pancreatitis, ventricular arrhythmias, heart failure with reduced ejection fraction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. https://app.cochat.ai/papers/10.1097/crd.0000000000001139
- The paper
- Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025). Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes. Cardiology in Review. https://doi.org/10.1097/crd.0000000000001139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.